Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study.

Weidinger S, Blauvelt A, Papp KA, Reich A, Lee CH, Worm M, Lynde C, Kataoka Y, Foley P, Wei X, Wong W, Solente AC, Weber C, Adelman S, Davey S, Hurbin F, Rynkiewicz N, Yen K, O'Malley JT, Bernigaud C

Open source

DOI: 10.1080/1750743x.2025.2545172
Published: 2025 Aug
Container: Immunotherapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/1750743x.2025.2545172,
  title = {Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study.},
  author = {Weidinger S and Blauvelt A and Papp KA and Reich A and Lee CH and Worm M and Lynde C and Kataoka Y and Foley P and Wei X and Wong W and Solente AC and Weber C and Adelman S and Davey S and Hurbin F and Rynkiewicz N and Yen K and O'Malley JT and Bernigaud C},
  year = {2025},
  journal = {Immunotherapy},
  doi = {10.1080/1750743x.2025.2545172},
  url = {https://doi.org/10.1080/1750743x.2025.2545172}
}

RIS

TY  - JOUR
TI  - Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study.
AU  - Weidinger S
AU  - Blauvelt A
AU  - Papp KA
AU  - Reich A
AU  - Lee CH
AU  - Worm M
AU  - Lynde C
AU  - Kataoka Y
AU  - Foley P
AU  - Wei X
AU  - Wong W
AU  - Solente AC
AU  - Weber C
AU  - Adelman S
AU  - Davey S
AU  - Hurbin F
AU  - Rynkiewicz N
AU  - Yen K
AU  - O'Malley JT
AU  - Bernigaud C
PY  - 2025
JO  - Immunotherapy
DO  - 10.1080/1750743x.2025.2545172
UR  - https://doi.org/10.1080/1750743x.2025.2545172
ER  -

APA

S, W., A, B., KA, P., A, R., CH, L., M, W., C, L., Y, K., P, F., X, W., W, W., AC, S., C, W., S, A., S, D., F, H., N, R., K, Y., JT, O., & C, B. (2025). Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study.. Immunotherapy. https://doi.org/10.1080/1750743x.2025.2545172

Source records

pubmed · retrieved 2026-09-26T06:10:37.174Z